

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁

Wenzhou Kangning Hospital Co., Ltd.

溫州康寧醫院股份有限公司

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2120)

ANNUAL REPORT OF THE COMPANY FOR THE YEAR ENDED DECEMBER 31, 2015

1. INTRODUCTION

1.1 The board of directors (the **Board**) of Wenzhou Kangning Hospital Co., Ltd. (the **Company**) is pleased to announce the consolidated annual report of the Company for the year ended December 31, 2015 (the **Reporting Period**). This report is prepared in accordance with the accounting standards and principles of the People's Republic of China.

1.2 The financial statements of the Company for the Reporting Period (the **Financial Statements**) are prepared in accordance with the International Financial Reporting Standards (the **IFRS**s).

2 FINANCIAL SUMMARY

2.1 Principal Financial Data and Indicators

	For the year ended December 31,			
	2015	2014	2013	2012
	RMB'000	RMB'000	RMB'000	RMB'000
Revenue	343,674	296,296	226,363	170,813
Profit before income tax	70,170	68,567	47,576	17,964
Income tax expense	(18,548)	(17,369)	(11,383)	(4,733)
Total comprehensive income	51,622	51,198	36,193	13,231
Attributable to:				
Equity holders of the Company	55,709	51,198	36,193	13,231
Non-controlling interests	(4,087)			

	As of December 31,			
	2015	2014	2013	2012
	RMB'000	RMB'000	RMB'000	RMB'000
Total assets	1,224,434	372,339	305,679	226,667
Total liabilities	262,205	111,249	96,818	202,601
Total equity	962,229	261,090	208,861	24,066
Equity attributable to:				
Equity holders of the Company	959,716	261,090	208,861	24,066
Non-controlling interests	2,513			

3 B N E P E N E A D O 100

3.1 Business Preview

I 2015, he G₁ c₁ i₁ , l e ha ced he e a i al ca abili e f i h₁ i al e_w k, facili a ed e , ce ha i g a g i e be h₁ i al a d i ed e a i al efficie c₁ ia ce e - a elli e del. I 2015, he fi e h₁ i al w₁ ed b₁ he G₁ e j ed g_w i g₁ , be f bed i e a i w₁ hich i c ea ed f 1,760 bed i 2014 2,010 i 2015, a d high, ili a i a e f bed w₁ hich ge e a ed able e e , ef he G₁ .

While c lida i g , w h i al b i e w e al ade a egic
la , i ke egi ac he c , a de e ed a ke i he egi
h , gh he a e -ligh e , e a age e del. I 2015, he G ,
a ed, de aki ge , e a age e f Ya jia F e H i al
f T adi i al Chi e a d We e Medici e* (燕郊輔仁中西醫結合醫
院, **anjiao F w en ospita**), he chia ic heal hca e de a e f
Che gd, Re i H i al C a Li i ed* (成都仁一醫院有限公司,
a i de e de hi d a e abli hed i he Pe le' Re , blic f Chi a
(he **P P C. China**) J e 29, 2010 a d i a e w a cha ged f
Che gd, Jih g H i al C a Li i ed* (成都濟宏醫院有限公司)
he c e e J l 28, 2015) a d Bei j i g Yi i g H i al C ., L d. (北
京怡寧醫院有限公司, **Beijin inin ospita**), i c ea i g he bed f
he edical facili ie , de i a age e f 150 i 2014 370 i 2015
a d la i g a lid f , da i f f he c , w ide e a i .

[illegible]

3.2 Business Vi h i hts

O Ja , a 22, 2016, he C a e e e d i (i) a f a w k a g e e e w
 i h We h , Medical U i e i * (溫州醫科大學) i e l a i he
 e d e a b l i h e a d e a i f he P c h i a Sch l f We h ,
 Medical U i e i * (溫州醫科大學精神醫學學院); a d (ii) a e a d
 f , de a d i g w i h We h , Medical U i e i A e Ma a g e e
 C a L i i e d * (溫州醫科大學資產經營有限公司) a d We h ,
 G , da I f a i Tech l g C a L i i e d * (溫州國大信息科技
 有限公司) i e l a i he e d a c , i i i f 51% f he e , i
 i e e i We h , G , da I e e C a * (溫州國大投資有限公

* *For identification purposes only*

司) b he C a f We h, Medical U i e i A e Ma age e C a Li i ed h, gh, blic biddi g, bjec he e e i g i f ele a f al age e e (). F de ail, lea e efe he C a ' a, ce e da ed Ja, a 22, 2016. The P chia Sch l f We h, Medical U i e i w a e abli hed Ma ch 20, 2016. A f he da e f hi a, ce e, he C a ha ac, i ed a e, i i e e i We h, G da I e e C a .

O Ja, a 28, 2016, he C a e e ed i a fa e k ag ee e w i h M . HUANG Fe g a d M . HUANG Che (c llec i el, he **endo s**.) i ela i (i) he ed e abli h e f a age c a (he **a et Company**.) b he Ve d ; (ii) he ed i i f a age e a d c, l a c e ice b he Ta ge C a P, jia g H a gfe g P chia S ecial H i al* (浦江黃鋒精神專科醫院) a d Ch, 'a H a gfe g Ka g'e H i al* (淳安黃鋒康恩醫院); a d (iii) he ed ac, i i i f 26% e, i i e e a d, b e, e ca i al i ce a e i he Ta ge C a b he C a (he **P oposed ansa tion**). U he c le i f he P ed Ta aci, i i e ec ed ha he C a w ill h ld 51% e, i i e e i he Ta ge C a . F de ail, lea e efe he C a ' a, ce e da ed Ja, a 28, 2016. The Ta ge C a w a e abli hed Feb, a 5, 2016. A f he da e f hi a, ce e, he C a ha e e ed i a age e e i ela i he P ed Ta aci .

O Feb, a 22, 2016, he C a e e ed i a a e hi age e e w i h Sha ghai Ji, Jia f, E, i I e e Ma age e C ., L d. (上海金浦健服股權投資管理有限公司, **inppv jianfv**), Sha ghai Yi che g A e Ma age e Ce e L.P. (上海銀驄資產管理中心 (有限合夥)), Ch g i g I d G da ce a d E, i I e e Fr d C ., L d. (重慶產業引導股權投資基金有限責任公司), Shi a Medical I, e C ., L d. (山東新華醫療器械股份有限公司), Jia g, Shaga g G, C ., L d. (江蘇沙鋼集團有限公司) a d USUM I e e G, C ., L d. (渝商投資集團股份有限公司) i ela i (i) he e abli h e f Ch g i g Ji, Heal hca e Se ice I d ial E, i I e e Fr d L.P.* (重慶金浦醫療健康服務產業股權投資基金合夥企業 (有限合夥)) (he **Investment Fvnd**); a d (ii) he C a ' c ib, i f RMB50.0 illi f he, b c i i he I e e Fr d. O he a e da e, he C a a d Ji, Jia f, he a agi g a e f he I e e Fr d, e e ed i a a egic c e a i age e e i ela i, a g he, ce ai igh f he C a a ali i ed a e f he I e e Fr d. F de ail, lea e efe he C a ' a, ce e da ed Feb, a 23, 2016. The I e e Fr d w a e abli hed i he PRC Ma ch 22, 2016. A f he da e f hi a, ce e, ch c ib, i ha bee a de a d he C a e ec ake, ch c ib, i i 2016.

* For identification purposes only

3.3 Business Outlook

L k i g i h e f , e , h e C a w ill f l l e e a g e h e f a a b l e
g e e l i c i e i C h i a w h i c h e c , a g e h e , b l i c e a b l i h
e d i c a l f a c i l i e a d a , a d e a d , h e a l h c a e f a c i l i e w k
h , g h e i g e w e d h i a l i 2016. I i e e c e d h a L i h a i
K a g i g H i a l C . , L d . * (臨海康寧醫院有限公司) (Linhai an nin
h o s p i t a) a d W e h , Y i i g G e i a i c H i a l C . , L d . * (溫州怡寧老
年醫院有限公司) (en h o w i n i n e i a t i o h o s p i t a , a h l l w e d
b i d i a f h e C a w h i c h w a e f e e d a h e L , i a M e d i c a l
A e a i h e e c , f h e C a d a e d N e b e 10, 2015 (h e
P o s p e c t i v s .) a d w h e i c i a l b r i e i i d e e d i c a l e i c e
f h e g e i a i c , i c h d i g g e i a i c c h i a i c c h l g i c a l e a e w ill
c e c e e a i i h e f i h a l f f 2016. A h e a e i e w e w ill a l
e e d , h e e a a i f h e e i g f P i g a g K a g i g H i a l *
(平陽康寧醫院) , Q h , Y i i g H i a l * (衢州怡寧醫院) a d S h e h e
Y i i g H i a l * (深圳怡寧醫院) , a i i g f h e c e c e e a i
i h e e c d h a l f f 2016.

Meawhile, he has launched the Entrepreneurial Piggy Bank 100 People (百人創業計劃), a daily challenge with a fascinating and interesting, celebratory and healing and facilitating environment for the group, which has been in place since 2016. In addition, the Center will continue to adhere to belief in global acceptance and healing, creating a new World Medical University in the Pacific School of World Medical University, which has been established in the Pacific region and is a global leader in the field of health and healing.

4 A A E E D C O A D A A V

4.1 Financial Review

4.1.1 Revenue

The G e , g e e a e e e , e ai l h , gh he f ll_wi g_w_wa : (i)
e e , e f e a i g i w ed h i al , a d (ii) a age e fee
f a agi g heal hca e facili ie .

* For identification purposes only

Company fee, referred to the total income of RMB206.3 million, increased by 15.4% which mainly resulted from the increase of the Group's management service fee income (2014: 37.5%).

Management service fee income

The Group's management service fee income is mainly derived from the design and construction of the healthcare facilities. The balance of the total management service fee income is accounted for the following:

	For the year ended	
	December 31,	
	2015	2014
	(RMB'000)	(RMB'000)
Revenue	13,561	10,294
Company fee	7,006	2,547
Group fee	6,555	7,747

Management service fee income of the Group amounted to RMB13.6 million, increased by 31.7% and accounted for 3.9% of the total revenue of the Group for 2015, down from the contribution of the management fee income in the year ended Beijing Yigong Hospital 2015 which amounted to RMB1.7 million (2014: nil).

Company fee of the Group is derived from the design and construction of the facilities for the management of the affiliated hospitals.

Company fee of the management service income amounted to RMB7.0 million, increased by 175.1%, mainly resulting from the increase of the fee, mainly because of the Al 2015 which was the first time of the Ya Jia Fei Hospital. The Group accounted for 19% and 9% of the total income of the hospital and accounted for RMB93.1 million of the total income of the hospital. RMB3.5 million which was the first time of the hospital in 2015 accounted for the management service fee. Accordingly, the Group's management service fee income decreased by 48.3% (2014: 75.3%).

4.1.2 Gross Profit and Gross Profit Margin

[illegible]

4.1.3 Other Income

On the other hand, the government's fiscal policy is also a key factor. In 2015, the government's fiscal policy was to increase the fiscal deficit by RMB3.1 trillion, which is a significant increase from the previous year's 346.2%, indicating a more aggressive fiscal policy.

4.1.4 Selling Expenses

In 2015, the electricity generated by the Grid, added RMB2.0 billion, increased significantly - - decreased by 5.8%, accounting for 0.6% of the total electricity (2014: 0.7%).

4.1.5 Administrative Expenses

Ad i i a i e e e e f he G , i a il c i f be efi
a d e e e f , a age e a dad i i a i e aff, e e e
f he e 1 -b il h i al i hei c e ce e f e a i ,
de ecia i , a i a i a d he .

I 2015, ad i i a i e e e e f he G , a , ed RMB62.5 illi (2014: RMB45.6 illi), e e e i g a e a - - e a i c e a e f 37.1%, i a i l d e : (i) a i c e a e f RMB6.2 illi i , e l e e b e e f i a d e e e a a e , l f (1) h e i c e a e i , a a g e e , e e a c h a d a d i i a i e a f f a d (2) e f a c e - b a e d b , e d i i b , e d h e e l e e f h e i c i b , i , b i e g w h; (ii) a i c e a e f RMB3.2 illi i h e e a l f e e f W e h , Y i i g G e i a i c H i a l w h i c h i e c e e c e e a i ; a d (iii) a i c e a e f RMB5.2 illi i h e e - f f l i i g e e e e l a e d , i i i a l , b l i c f f e i g .

4.1.6 Finance Income

In 2015, finance income increased RMB7.6 million, increasing year-on-year income of 917.8%, mainly because the credit loss provision for the initial public offering of the H K Guangdong (USD). Higher charge of HK\$ against Rebi (RMB) increased the realized charge gain by RMB9.8 million, which offset the finance expense of 1 million, resulting in a net gain of RMB4.0 million.

4.1.7 Share of Loss of Investments Accounted for Using the Equity Method

In 2015, the share of loss accounted for using the equity method decreased RMB6.3 million (2014: nil), which decreased by 49% compared to Beijing Yigong He Industrial, which contributed to the share of loss in 2015 and decreased by 1 million from RMB12.8 million.

4.1.8 Income Tax Expense

In 2015, income tax expense increased RMB18.5 million, increasing year-on-year income of 6.8%, mainly due to the higher provision of RMB70.2 million (2014: RMB68.6 million). The effective rate in 2015 and 2014 was 26.4% and 25.3%, respectively.

4.1.9 Net Profit

In 2015, the attributable net profit of the Company (the consolidated) decreased RMB55.7 million, increasing year-on-year income of 8.8% compared with 2014.

4.2 Financial Position

4.2.1 Inventory

As of December 31, 2015, the balance decreased RMB7.5 million (as of December 31, 2014: RMB7.9 million), mainly due to the decrease in the carrying value.

4.2.2 Trade Receivables

As of December 31, 2015, the balance of trade receivables increased RMB123.1 million (as of December 31, 2014: RMB84.5 million), mainly due to: (i) the increase in revenue from the sale of medical equipment, which has been recognized as revenue; and (ii) the increase in the balance of trade receivables from the sale of medical equipment. As of December 31, 2015, 79.5% of trade receivables from the Group were aged within 90 days.

4.2.3 Other Receivables, Deposits and Prepayments

As of December 31, 2015, the receivables, deposits and prepayments increased RMB91.0 million (as of December 31, 2014: RMB41.2 million), mainly due to: (i) the increase of RMB25.8 million in deposits from the sale of land use rights in Weihai, Yiting Geiaic Hospital; (ii) the increase of RMB13.0 million in deposits from the sale of shares in Pingyang Kangning Hospital Co., Ltd.* (平陽康寧醫院有限公司) (Pingyang Kangning Hospital Co., Ltd.*); and (iii) the increase of RMB12.0 million in deposits from the sale of shares in Pingyang Kangning Hospital Co., Ltd.*.

4.2.4 Trade Payables

As of December 31, 2015, the payable decreased RMB20.0 million (as of December 31, 2014: RMB23.8 million), of which 84.5% were aged within 90 days.

4.2.5 Accruals and Other Payables

As of December 31, 2015, accruals and other payables increased RMB166.4 million (as of December 31, 2014: RMB60.0 million), mainly due to RMB90.5 million of accruals from the sale of land use rights in Weihai, Yiting Geiaic Hospital, which has been recognized as revenue; and the increase of RMB75.9 million in accruals from the sale of shares in Pingyang Kangning Hospital Co., Ltd.*. The increase of RMB166.4 million in accruals and other payables is mainly due to the increase of RMB90.5 million in accruals from the sale of land use rights in Weihai, Yiting Geiaic Hospital, which has been recognized as revenue; and the increase of RMB75.9 million in accruals from the sale of shares in Pingyang Kangning Hospital Co., Ltd.*.

4.2.6 Net Current Assets

As of December 31, 2015, the net current assets of the Group increased RMB664.0 million (as of December 31, 2014: RMB86.2 million), mainly due to the increase of RMB590.7 million in net current assets from the sale of land use rights in Weihai, Yiting Geiaic Hospital, which has been recognized as revenue; and the increase of RMB50.0 million in net current assets from the sale of shares in Pingyang Kangning Hospital Co., Ltd.*.

* For identification purposes only

4.3 Diversity and Capital Resources

The able bel_v of h he i f a i a e ac ed f he c lida ed
ca h fl_v a e e f he G , f he e i d i dica ed:

Year ended December 31,

	2015	2014
	RMB'000	RMB'000
Net cash/(used)/received in operating activities	(5,063)	33,328
Net cash/(used)/received in investing activities	(382,367)	(60,663)
Net cash/(used)/received in financing activities	708,785	(2,977)
Net increase/(decrease) in cash and cash equivalents	321,355	(30,312)

4.3.1 Net Cash from Operating Activities

I 2015, e ca h , fl_w f e a i g a c i i e a , ed RMB5.1 illi . We had e ca h g e e a e d f e a i g a c i i e b e f e c h a g e i_w k i g c a i a l f RMB87.0 illi , i a i l c i i g f f i b e f e a f RMB70.2 illi a d a d j , e f d e c i a i f , e , l a a d e , i e f RMB17.3 illi . C h a g e i_w k i g c a i a l e , l e d i c a h , fl_w f RMB66.4 illi , i a i l c i i g f a i c e a e f RMB58.2 illi i a d e a d h e e c e i a b l e a a e , l f : (i) i c e a e d e a e l e a i b , a b l e h e c i , e d e a i a d c a l i g , f , h e a l h c a e f a c i l i e e_w k ; a d (ii) , e a e f e a l e e e e l a i g . We h , Y i i g G e i a i c H i a l . We had f h e c a h , fl_w f RMB25.7 illi a i b , a b l e , i c e a a i d .

4.3.2 Net Cash Used in Investing Activities

I 2015, e ca h, ed i i e i g a c i i e a , ed RMB382.4 illi , i a i l d e : (i), cha e f , la a d e, i e f RMB113.6 illi , c i i g f (1) a , aid a d e aid e a e a d, g a d e We h , Ka g i g H i a l a d (2) a , aid e a e Bei j i g Yi i g H i a l, Li hai Ka g i g H i a l a d We h , Yi i g Ge i a i c H i a l i h e i g; a d (ii) a e d e i w i h i i i a l e e h e e h f RMB251.3 illi .

4.4 Indebtedness

4.4.1 Bank Borrowings

As of December 31, 2015, the balance of bank borrowings of the Group, secured RMB50.0 million (as of December 31, 2014: nil), all due within one year.

4.4.2 Contingent Liabilities

As of December 31, 2015, the Group had contingent liabilities guaranteed by Wanda, including a special dividend of the financial institution of the Group.

4.4.3 Asset Pledge

As of December 31, 2015, the Group's assets had been pledged.

4.4.4 Contractual Obligations

The contractual obligations of the Group include financial lease agreements. As of December 31, 2015, the future aggregate financial lease agreements, including cancellable lease agreements were RMB209.0 million.

4.4.5 Financial Instruments

Financial instruments of the Group consist of receivables, accounts payable, other receivables, the receivables, deposits, cash and cash equivalents, bank borrowings, and other payable. The management manages and monitors the financial instruments, and manages the financial instruments to ensure the effective operation.

4.4.6 Exposure to Fluctuation in Exchange Rates

The Group's debt is denominated in US dollars, and is subject to exchange rate fluctuations against the Hong Kong dollar. The Group's exposure to exchange rate fluctuations is managed through the use of foreign exchange derivatives.

The Group has entered into foreign exchange derivatives contracts to hedge its exposure to exchange rate fluctuations. The Group's foreign exchange derivatives contracts are denominated in US dollars and are used to hedge its exposure to exchange rate fluctuations.

4.4.7 Gearing Ratio

As at December 31, 2015, the Group's gearing ratio (total debt divided by total assets) was 11.8% (2014: 10.5%).

5 FINANCIAL RESULTS

5.1 Issuance of Shares and Dividends

The Company's share capital is denominated in US dollars. The Shareholders' Agreement (the "Shareholders' Agreement") provides that the Company shall not issue any new shares without the approval of the Shareholders. As at December 31, 2015, the Company's share capital was HK\$693.2 million (equivalent to RMB580.7 million) and the Company's share premium was HK\$1,000 million. As at the end of the reporting period, the Company's share capital was HK\$693.2 million (equivalent to RMB580.7 million) and the Company's share premium was HK\$1,000 million.

5.2 Dividend

The final dividend for the year ended December 31, 2015 (the "Proposed Final Dividend") was approved by the Shareholders at the Annual General Meeting of the Company held on January 14, 2016. The Proposed Final Dividend will be paid to the Shareholders on or after January 14, 2016. The Shareholders' Agreement provides that the Company shall not pay any dividend without the approval of the Shareholders.

The dividend for the year ended March 15, 2016 (the "Proposed Dividend") was approved by the Shareholders at the Annual General Meeting of the Company held on January 14, 2016. The Proposed Dividend will be paid to the Shareholders on or after January 14, 2016.

If he i di id, al h lde f H Sha e a e H g K g Maca, e ide e ide f he c, ie w^hich had a agreeed a a e f 10% f he ca h di ide d he w^hi h he PRC, de he ele a a agree e, he C a h, ld w^hi hh ld a d, a i di id, al i c e a behalf f he ele a Sha eh lde a a a e f 10%. Sh, ld he i di id, al h lde f H Sha e be e ide f he c, ie w^hich had a agreeed a a e f le ha 10% w^hi h he PRC, de he ele a a agree e, he C a hall w^hi hh ld a d, a i di id, al i c e a behalf f he ele a Sha eh lde a a a e f 10%. I ha ca e, if he ele a i di id, al h lde f H Sha e w^hi h eclai he e a a, w^hi h held d e he a lica i f 10% a a e, he C a ca a l f he ele a agreeed e fe e ial a e a e ided ha he ele a Sha eh lde, b i he e ide ce e, i ed b he ice f he a agree e C, e ha e. The C a w^hill a i w^hi h he a ef, d a fe he a l f he c e e a a h i. Sh, ld he i di id, al h lde f H Sha e be e ide f he c, ie w^hich had a agreeed a a e f e 10% b, le ha 20% w^hi h he PRC, de he a agree e, he C a hall w^hi hh ld a d, a he i di id, al i c e a a he agreeed ac, al a e i acc da ce w^hi h he ele a a agree e. I he ca e ha he i di id, al h lde f H Sha e a e e ide f he c, ie w^hich had a agreeed a a e f 20% w^hi h PRC, w^hich ha e e ed i a a agree e w^hi h PRC, he w^hi e, he C a hall w^hi hh ld a d, a he i di id, al i c e a a a a e f 20%.

5.3 P w phase, a e and Redemption of Listed e w ities

Dr i g he, e i d f he Li i g Da e Dece be 31, 2015, ei he he C a a a fi, b idia ie, cha ed, ld edee ed a f he C a ' li ed ec, i ie.

5.4 Review of Annva Presnts

The C a ' a di c i ee ha e ie^hed he G, ' a, al e, l f he fi a cial ea e ded Dece be 31, 2015 a d ha i ed ha a lica ble acc, i g a da d a d e, i e e ha e bee c l ied w^hi h a d ha ade, a e di cl, e ha e bee ade b he C a.

The C a ' a di c i ee c i f w^hi de e de -e ec, i e di ec f he C a, M. HUANG Zhi (he chai a f he a, di c i ee) a d M. WONG Ra d F k La, a d e -e ec, i e di ec f he C a, M. HE Xi. A g he, M. HUANG Zhi ha he a l i a e, fe i al, alifica i (a ce ified, blic acc, a acc edi ed b he Chi e e I i, e f Ce ified P blic Acc, a (中國註冊會計師協會)).

6 CO P T A C E X X C O P T A E O E P A C E CODE

The C... a c ... lied w... i h all c de... i i ... i he C... ae G e a ce
C de (he Co po ate ove nan e Code) e , i A... e di 14 he R le
G e i g he Li i g f Sec, i ie The S ck E cha ge f H g K g
Li i ed d i g he e i d f he Li i g Da e Dece be 31, 2015, a e f
he de ia i f c de... i i A.2.7 w... hich w... a... i a il d e he h
e i d f i e f he Li i g Da e Dece be 31, 2015. C de... i i
A.2.7 e, i e ha he chai a h l d a lea a , all h ld ee i g w... i h he
-e ec, i e di ec (i cl, di g i de e de -e ec, i e di ec) w... i h,
he e ec, i e di ec e e . The C... a ha c i ed aki g ece a
a a ge e c l w... i h all he c de... i i . The C... a w... ill c i, e
e i e w... a d e ha ce i c a e g e a ce e , e ha i w... ill c i, e
ee he e, i e e f he C... ae G e a ce C de.

7 FINAL CHAPTER

7.1 Scope of work of private house Cooper's

[illegible]

7.2 Accountin po isies

Casa ed el la ar di ed fi a cial a e e f he G , he e a e
ig ifica cha ge acc , i g licie .

7.3 Financial statements

7.3.1 Consolidated Statement of Comprehensive Income

	Year ended December 31, 2015 RMB'000	2014 RMB'000
Revenue	343,674	296,296
Cost of revenue	(213,289)	(181,313)
Gross profit	130,385	114,983
Operating expenses	3,074	689
Other income	(144)	(151)
Selling expenses	(1,970)	(2,092)
Administrative expenses	(62,520)	(45,611)
Operating profit	68,825	67,818
Financial income	11,625	749
Financial expenses	(4,002)	
Finance income – net	7,623	749
Share of profits of associates accounted for, including dividends	(6,278)	
Profit before income tax	70,170	68,567
Income tax expense	(18,548)	(17,369)
Net profit	51,622	51,198
Other comprehensive income	–	
Total comprehensive income	51,622	51,198
Attributable to:		
Equity holders of the Company	55,709	51,198
Non-controlling interests	(4,087)	
Earnings per share		
Basic and diluted (in RMB)	1.03	1.02

7.3.2 Consolidated Balance Sheets

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Assets		
Non-current assets		
Property, plant and equipment	233,200	160,799
Land use right	20,738	21,210
Intangible assets	90,581	1,229
Investment in associates	8,422	
Deferred income taxes	10,071	4,641
Derivative assets	48,324	13,904
Total non-current assets	411,336	201,783
Current assets		
Inventory	7,506	7,911
Trade receivable	123,067	84,532
Other receivable, derivative assets	42,690	27,340
Accounts payable	20,044	13,502
Prepaid expenses	251,334	
Cash and cash equivalents	368,457	37,271
Total current assets	813,098	170,556
Total assets	1,224,434	372,339
Equity		
Equity attributable to owners of the Company		
Share capital	73,040	50,000
Capital reserve	797,510	159,153
Surplus reserve	11,342	5,708
Retained earnings	77,824	46,229
	959,716	261,090
Non-controlling interest	2,513	
Total equity	962,229	261,090

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
LIABILITIES		
non-current liabilities		
Deferred government grants	14,284	14,156
Long-term payable	98,821	12,688
total non-current liabilities	113,105	26,844
Current liabilities		
Trade payable	19,976	23,829
Accrual and other payable	63,209	47,340
Contractual liabilities	11,559	13,236
Bank borrowings	50,000	
Current financial payable	4,356	
total current liabilities	149,100	84,405
total liabilities	262,205	111,249
total equity and liabilities	1,224,434	372,339

7.4 Notes to the Financial Statements

7.4.1 General Information

The Company was established as a joint stock company in the People's Republic of China, under the name of Weishan Kangning Mental Healthcare Hospital (溫州市康寧精神康復醫院) in the PRC on February 7, 1996. The address of the Company's registered office is a Shengji Road, Hangzhou Residential District, Weishan, Zhejiang, the PRC.

On October 15, 2014, the Company was converted into a joint stock limited company named Weishan Kangning Hospital Co., Ltd. (溫州康寧醫院股份有限公司).

The Company is engaged in the healthcare industry in the PRC.

The Company had no public listing on the Stock Exchange of Hong Kong since November 20, 2015.

The consolidated financial statements are prepared in RMB and expressed in the PRC Renminbi, and all figures are in thousands of RMB unless otherwise indicated.

7.4.2 Basis of Preparation

The consolidated financial statements of the Group have been prepared in accordance with the IFRS. The consolidated financial statements have been prepared, under the historical cost convention.

(a) New and amended standards adopted by the Group

The following standards and amendments have been adopted by the Group from the effective date of the financial reporting period ended 31 January 2015:

Amended IAS 19 Contributions to defined benefit plans.

Amended financial instruments IFRS 2010-2012 Cycle, IFRS 8, 'Operating segments', IAS 16, 'Property, plant and equipment', IAS 38, 'Intangible assets' and IAS 24, 'Related party disclosures'.

Amended financial instruments IFRS 2011-2013 Cycle, IFRS 3, 'Business combinations', IFRS 13, 'Fair value measurement'.

Amended IAS 27 'Earnings per share financial statement'.

The directors of the Company are advised that the adoption of the newly adopted IFRS had no material impact on the Group's earnings, financial position.

(b) New Hong Kong Companies Ordinance (Cap. 622)

In addition, the relevant provisions of Part 9 Accounts and Audits of the new Hong Kong Companies Ordinance (Cap. 622) came into effect during the financial year, as a result, the accounting treatment of the related disclosures of the financial statements of the consolidated financial statements.

(c) *New standards and interpretations not yet adopted*

As at the end of the reporting period, the Group has not yet adopted the new standards and interpretations that are effective for the first time for the reporting period commencing on or after January 1, 2015 and have been applied in the accounting period ended financial year. The effects of the new standards and interpretations on the Group's financial position, performance and cash flows are not yet quantifiable. The Group has not yet adopted the new standards and interpretations that are effective for the first time for the reporting period commencing on or after January 1, 2015 and have been applied in the accounting period ended financial year. The effects of the new standards and interpretations on the Group's financial position, performance and cash flows are not yet quantifiable.

IFRS 9, 'Financial Instruments'

IFRS 15, 'Revenue from Contracts with Customers'

IFRS 16, 'Leases'

The effects of the IFRS and IFRIC interpretations have not yet been determined. The Group has not yet adopted the new standards and interpretations that are effective for the first time for the reporting period commencing on or after January 1, 2015 and have been applied in the accounting period ended financial year. The effects of the new standards and interpretations on the Group's financial position, performance and cash flows are not yet quantifiable.

7.4.3 Trade Receivables

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Trade receivable	130,738	89,537
Less: provision for doubtful trade receivable	(7,671)	(5,005)
Trade receivable net	<u>123,067</u>	<u>84,532</u>

The carrying amount of the Group's trade receivable as at the end of the reporting period is RMB123,067,000, which is fully collectible.

As of December 31, 2014 and 2015, the aggregate liability for the deductible expenses was as follows:

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Aggregate liability based on the billings data:		
Bill incurred	9,580	9,927
1-3 months	74,718	45,694
4-6 months	19,635	13,082
7-12 months	19,937	14,635
1-2 years	5,075	4,574
2-3 years	1,426	1,544
Over 3 years	367	81
	<u>130,738</u>	<u>89,537</u>

According to the Group's effective benefit plan, all billable expenses are paid.

As of December 31, 2014 and 2015, the Group's deductible and deductible expenses were RMB73,442,000 and RMB113,297,000, respectively. The deductible expenses are claimed for full tax credit, and the deductible expenses are deductible for the deductible expenses of medical expenses which are deductible for the deductible expenses of medical expenses which are deductible for the deductible expenses of medical expenses.

The management considers that the deductible expenses are high and can be reduced in the future. The aggregate liability for the deductible expenses was as follows:

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Leasehold	110,355	71,136
1-2 years	2,800	2,269
2-3 years	142	3
Over 3 years	—	34
	<u>113,297</u>	<u>73,442</u>

As of December 31, 2014 and 2015, the receivable of RMB6,168,000 and RMB7,861,000, respectively, are included. The amount of the receivable of RMB5,005,000 and RMB7,671,000 as of December 31, 2014 and 2015, respectively. The aging of the receivable is as follows:

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Less than 1 year	3,935	2,275
1-2 years	2,275	2,305
2-3 years	1,284	1,541
Over 3 years	367	47
	<u>7,861</u>	<u>6,168</u>

The amount of the Group's receivable from the sale of the receivable is as follows:

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
At January 1,	5,005	3,699
Provision of receivable	4,907	2,957
Receivable of the affiliated companies	(2,241)	(1,304)
Write-back, net	-	(347)
At December 31,	<u>7,671</u>	<u>5,005</u>

The provision of receivable included in the consolidated statement of comprehensive income. All of the receivable are expected to be collected within one year.

The amount of the receivable from the sale of the receivable is as follows. The Group does not have any receivable from the sale of the receivable.

7.4.4 Other Receivables, Deposits and Prepayments

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Other receivable ^(a)	14,337	1,408
Deposit ^(b)	17,268	16,823
Accounts receivable ^(c)	12,304	
Prepaid expense	30,007	16,686
Prepaid purchase price ^(d)	13,000	
Prepaid consulting fee	2,594	1,216
Prepaid goods purchase	2,539	1,511
Prepaid IPO expense	–	3,477
Other	43	123
Less: impairment of other receivable	(1,078)	
Total	91,014	41,244
Current	42,690	27,340
Non-Current	48,324	13,904
Total	91,014	41,244

The carrying amount of the Group's other receivable, deposit and prepaid expense as of December 31, 2015 is RMB91,014,000 and as of December 31, 2014 is RMB41,244,000.

(a) Included in other receivable as of December 31, 2015, is a receivable of RMB9,210,000 from Ya Jia Fei He Hui. Such receivable will be paid by the Group to Ya Jia Fei He Hui when the cash flow is available.

(b) Included in deposit as of December 31, 2014 and 2015, is a deposit of RMB12,688,000 from the cash account of the company. Such deposit is a prepayment for the purchase of the Group's shares. The deposit will be paid by the Group after the shares are completed and all Group's obligations have been discharged.

(c) The Company entered into an agreement with Sichuan Hongji Pacific Capital Limited (Chen Wanji, a subsidiary of the Company) in March 2015 and placed a deposit of RMB12,000,000 with Sichuan Hongji. The Company called a share subscription. Subsequently, the agreement was cancelled and the Company agreed to withdraw the deposit from Sichuan Hongji. Chengdu Jihong Hui Capital Limited (Chen Dawu, a subsidiary of the Company) is a

f Sichuan Hengji) and the Company. June 29, 2015. Pursuant to the relevant agreement, the two parties agreed to abandon the business relationship, and the debt should be paid by Chengdu Jihong Group. On July 12, 2015, the company signed a letter of intent with Jihong Group, according to which the company should pay the debt of Jihong Group within 12 months. The amount of the debt is RMB18,000,000. On December 31, 2015, the company has not yet paid the debt of Jihong Group.

On July 28, 2015, Chengdu Jihong Group changed its name to Chengdu Reihong Chemical Co., Ltd.

(d) The Company entered into an agreement with Pinggang Mining Specialized Fund Co., Ltd. (Pinggang Mining), a private equity fund, in October 2015, to raise a total of RMB18,000,000. The total contribution of the company is RMB18,000,000. As of December 31, 2015, the company has not yet paid Pinggang Mining.

7.4.5 Accruals and Other Payables

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Accrued employee benefits	18,637	17,939
Receivable interest	3,194	3,416
Receivable	3,004	3,362
Grantee deposits received from		
customers (a)	12,688	12,688
Other payable for purchase of land and		
equipment	20,831	19,916
Other payable	412	641
Advance received from customers		
Hengde (b)	3,110	1,500
Long-term payable for acquisition		
of the company	90,489	
Accrued liability for interest	11,606	
Other	2,415	566
total	166,386	60,028
Current	63,209	47,340
Current liability for long-term payable		
for acquisition of the company	4,356	
Non-current	98,821	12,688
total	166,386	60,028

The carrying amount of the available-for-sale financial assets is RMB. The carrying amount of the available-for-sale financial assets is RMB. The carrying amount of the available-for-sale financial assets is RMB.

- (a) The amount of the carrying amount of the available-for-sale financial assets is RMB. The amount of the carrying amount of the available-for-sale financial assets is RMB. The amount of the carrying amount of the available-for-sale financial assets is RMB.
- (b) The amount of the carrying amount of the available-for-sale financial assets is RMB. The amount of the carrying amount of the available-for-sale financial assets is RMB. The amount of the carrying amount of the available-for-sale financial assets is RMB.

7.4.6 Revenue

	Year ended December 31,	
	2015	2014
	RMB'000	RMB'000
Tea and other health care products	240,103	206,790
Pharmaceuticals	87,740	77,384
Acupuncture and other health care services	2,270	1,828
Management fee	13,561	10,294
	343,674	296,296

7.4.7 Expenses by Nature

	Year ended December 31,	
	2015	2014
	RMB'000	RMB'000
Employee benefits	99,988	82,750
Pharmaceuticals and medical	86,483	75,419
Deceit and damage	21,706	15,067
Quota of general expenses	8,563	10,055
Quota of general expenses for medical facilities	7,388	6,612
Care expenses	11,280	8,404
Utilities	5,820	5,381
Education and training fee	3,388	3,900
Professional fees and other	4,907	2,610
Professional fees and other	1,078	
Tax expenses	2,481	3,086
Printing and mailing	1,970	2,092
Dental charges	1,814	1,834
Charitable aid	345	1,147
Living expenses	5,177	
Advertising expenses		
Advertising	1,532	315
Non-advertising	—	
Other	13,859	10,344
	277,779	229,016

7.4.8 Income Tax Expense

The income tax expense of the Group for the year ended December 31, 2014 and 2015 is analyzed as follows:

	Year ended December 31,	
	2015	2014
	RMB'000	RMB'000
Current income tax:		
PRC corporate income tax	23,978	19,054
Deferred income tax	(5,430)	(1,685)
	<u>18,548</u>	<u>17,369</u>

The amount of the Group's provision for income tax differs from the theoretical amount, calculated at the rate applicable in the PRC, due to the following factors:

	Year ended December 31,	
	2015	2014
	RMB'000	RMB'000
Provision for income tax	70,170	68,567
Calculated at the rate of 25%	17,543	17,142
Excess deductible	2,507	227
Income tax rebates	(167)	
Other adjustments	(1,335)	
	<u>18,548</u>	<u>17,369</u>

PRC corporate income tax

The income tax provision of the Group is calculated based on the income in the PRC has been calculated at the rate of 25% which is applied as available for the year, based on the existing legislation, income tax and administrative regulations, and other relevant laws and regulations applicable.

7.4.9 Earnings per Share

Basic earnings per share

The calculation of basic earnings per share is based on the attributable dividend, which is the dividend of the Company of RMB51,198,000 and RMB55,709,000 for the ended December 31, 2014 and 2015, respectively, and the weighted average number of shares outstanding for the period, as follows:

Weighted average number of ordinary shares

	Period ended December 31,	
	2015	2014
	No. of shares	No. of shares
Ordinary shares issued at beginning of the period	50,000,000	50,000,000
Effect of increase of shares	4,253,370	
Weighted average number of shares outstanding	<u>54,253,370</u>	<u>50,000,000</u>

The Company was established on October 15, 2014. The calculation of the Shares of the Company ended December 31, 2014 is based on 50,000,000 ordinary shares, which is the number of shares outstanding at the beginning of the period. The calculation of the Shares of the Company ended December 31, 2015 is based on 54,253,370 ordinary shares.

Diluted earnings per Share

The Company did not have any potential dilutive Shares, therefore, the diluted earnings per Share are the same as the basic earnings per Share.

7.4.10 Final Dividends

On March 11, 2015, the Board declared a final dividend of RMB18,480,000 for the year ended December 31, 2014. The dividend was paid to the shareholders on June 1, 2015 and the Company paid the dividend on July 23, 2015.

On March 24, 2016, the Board declared a final dividend of RMB18,260,000 for the year ended December 31, 2015, which is calculated based on 73,040,000 issued Shares as of December 31, 2015. The declared dividend will be reflected as a dividend payable in the consolidated financial statements as of December 31, 2015, and will be reflected as a liability in the consolidated statement of financial position as of December 31, 2016.

	Year ended December 31,	
	2015	2014
	RMB'000	RMB'000
Paid final dividend of RMB0.25 (2014: RMB0.35) to the Shareholders	<u><u>18,260</u></u>	<u><u>18,480</u></u>

7.4.11 Commitments

Capital commitments

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Contracted but not provided for		
construction building	36,635	86,130
leasehold improvements	60,529	1,784
other, including decoration	<u>10,935</u>	<u>794</u>
	<u><u>108,099</u></u>	<u><u>88,708</u></u>

Operating lease commitments

The Group lease certain office buildings and industrial premises on a non-cancellable lease agreement.

The Group's future aggregate minimum lease payments under non-cancellable operating leases are as follows:

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Non-lease liability	28,593	26,654
Lease liability and		
lease liability	74,546	80,867
Lease liability	105,831	129,116
	<u>208,970</u>	<u>236,637</u>

Investment in subsidiaries

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Non-lease liability	43,000	8,600
Lease liability and		
lease liability	15,600	2,400
	<u>58,600</u>	<u>11,000</u>

7.4.12 Principal Subsidiaries

The following is a list of the principal subsidiaries of the Company as at December 31, 2015:

Company Name	Place of incorporation and kind of legal entity	Principal activities and place of operation	Particulars of issued share capital and debt securities	Proportion of shares directly held by parent (%)	Proportion of shares held by the company (%)	Proportion of shares held by non-controlling interests (%)
Cangnan Kangning Hospital Co., Ltd. (蒼南康寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB1,000,000	100%	100%	
Qingdao Kangning Hospital Co., Ltd. (青島康寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB1,000,000	100%	100%	
Yongjia Kangning Hospital Co., Ltd. (永嘉康寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB1,000,000	100%	100%	
Yueqing Kangning Hospital Co., Ltd. (樂清康寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB1,000,000	100%	100%	
Shenzhen Yining Hospital Co., Ltd. (深圳市怡寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB16,600,000		52%	48%
Weihai Kangning Judicial Forensic Center (溫州康寧司法鑒定所)	The PRC, Sole proprietorship enterprise	Forensic identification in PRC	Paid-in capital of RMB500,000	100%	100%	
Linhai Kangning Hospital Co., Ltd. (臨海康寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB2,000,000	80%	80%	20%
Weihai Yining Geriatric Hospital Co., Ltd. (溫州怡寧老年醫院有限公司) ^(a)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB10,000,000	100%	100%	
Pingyang Kangning Hospital Co., Ltd. (平陽康寧醫院有限公司) ^(b)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB6,000,000	100%	100%	
Shenzhen Yining Medical Investment Co., Ltd. (深圳怡寧醫療投資有限公司) ^(c)	The PRC, Limited liability company	Investment holding in PRC	Nil	100%	100%	
Quzhou Yining Hospital Co., Ltd. (衢州怡寧醫院有限公司) ^(d)	The PRC, Limited liability company	Private hospital in PRC	Nil	60%	60%	40%
Hangzhou Honglan Information Technology Co., Ltd. (杭州宏瀾信息科技有限公司) ^(e)	The PRC, Limited liability company	Online medical consulting in PRC	Nil	100%	100%	
Lanfang Yining Hospital Management Co., Ltd. (廊坊市怡寧醫院管理有限公司) ^(f)	The PRC, Limited liability company	Hospital management consulting in PRC	Nil	100%	100%	

All the subsidiaries are established in the PRC and all issued liabilities are in the Renminbi. We have no significant financial commitments which are in foreign currencies.

- (a) We have no significant financial commitments, and we have established a new subsidiary in December 2015, which has a registered capital of RMB10,000,000. Its paid-up capital is RMB10,000,000 as of December 31, 2015.
- (b) Pinggang Kaigong Financial Co., Ltd. has established a new subsidiary in December 2015, which has a registered capital of RMB6,000,000. Its paid-up capital is RMB6,000,000 as of December 31, 2015.
- (c) Shehe Yig Medical Investment Co., Ltd. has established a new subsidiary in December 23, 2015, which has a registered capital of RMB10,000,000. Its paid-up capital is RMB10,000,000 as of December 31, 2015.
- (d) Qihang Yig Financial Co., Ltd. has established a new subsidiary in December 20, 2015, which has a registered capital of RMB30,000,000. Its paid-up capital is RMB30,000,000 as of December 31, 2015.
- (e) Hanghang Huiji Information Technology Co., Ltd. has established a new subsidiary in December 20, 2015, which has a registered capital of RMB5,000,000. Its paid-up capital is RMB5,000,000 as of December 31, 2015.
- (f) Laifang Yig Financial Management Co., Ltd. has established a new subsidiary in December 2, 2015, which has a registered capital of RMB10,000,000. Its paid-up capital is RMB10,000,000 as of December 31, 2015.

Board of Directors
Guangnan Hospital Co., Ltd.
Chairman

Zhejiang, the PRC
 March 29, 2016

As of the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive directors are Mr. YANG Yang and Ms. HE Xin; and the independent non-executive directors are Mr. CHONG Yat Keung, Mr. HUANG Zhi and Mr. WONG Raymond Fook Lam.